Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Arbutus Biopharma Corp changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 123 | 1 | 119 | −3 |
| Shares | 39.7M | 75 | 43.9M | +4.20M (+10.6%) |
| Value | $154.4M | $0 | $130.6M | −$23.8M (−15.4%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FourWorld Capital Management LLC | 1,547,739 | $4.61M | 2.86% |
| FMR LLC | 164,130 | $489.0K | 0.00% |
| Dynamic Technology Lab Private Ltd | 65,576 | $195.0K | 0.02% |
| HRT Financial LP | 50,617 | $150.0K | 0.00% |
| Oracle Investment Management Inc | 50,000 | $149.0K | 0.03% |
| Franklin Resources Inc | 45,900 | $137.0K | 0.00% |
| Gsa Capital Partners LLP | 32,453 | $97.0K | 0.01% |
| Verus Capital Partners, LLC | 28,600 | $72.0K | 0.01% |
| Bayesian Capital Management, LP | 12,100 | $36.0K | 0.01% |
| Leonteq Securities AG | 12,000 | $35.8K | 0.00% |
| Front Row Advisors LLC | 10,500 | $31.0K | 0.01% |
| Amalgamated Bank | 10,096 | $30.0K | 0.00% |
| Pathstone Family Office, LLC | 10,000 | $30.0K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 8,108 | $24.0K | 0.00% |
| Nisa Investment Advisors, LLC | 2,700 | $8.00K | 0.00% |
| Hantz Financial Services, Inc. | 350 | $1.00K | 0.00% |
| Ellevest, Inc. | 39 | $0 | 0.00% |
Sold out (20)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| RTW Investments, LP | 2,504,493 | $9.74M |
| Great Point Partners LLC | 668,907 | $2.60M |
| Quinn Opportunity Partners LLC | 276,485 | $1.08M |
| PointState Capital LP | 200,000 | $778.0K |
| Walleye Capital LLC | 172,229 | $670.0K |
| First Quadrant L P | 75,700 | $294.0K |
| Pitti Group Wealth Management, LLC | 50,000 | $195.0K |
| Walleye Trading LLC | 48,743 | $190.0K |
| Squarepoint Ops LLC | 40,014 | $156.0K |
| Schonfeld Strategic Advisors LLC | 12,500 | $49.0K |
| Belvedere Trading LLC | 17,579 | $47.0K |
| Credit Suisse AG | 11,271 | $44.0K |
| Traynor Capital Management, Inc. | 11,000 | $42.0K |
| QCM Cayman, Ltd. | 10,205 | $40.0K |
| Secure Asset Management, LLC | 10,000 | $39.0K |
| Bank Julius Baer & Co. Ltd, Zurich | 7,800 | $30.0K |
| TD Waterhouse Canada Inc. | 900 | $3.35K |
| Geneos Wealth Management Inc. | 1,000 | $3.00K |
| US Bancorp | 475 | $2.00K |
| Masso Torrence Wealth Management Inc. | 500 | $2.00K |
Not filed for Q1 2022 yet (1)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Reilly Financial Advisors, LLC | 75 | $0 |